|
Recommended for:
|
Reprogramming various cell types to iPSCs
|
|
Components:
|
1 vial of minicircle DNA, 100 µg/vial
|
|
Accessory Products:
|
• mTeSR®1 (Catalog #05850, #05870, #05875)
• TeSR™2 (Catalog #05860, #05880)
• EasySep® hESC/hiPSC SSEA-4 Positive Selection Kit (Catalog #18165)
• AggreWell™ 400 (Catalog #27845, #27945)
• AggreWell™ 800 (Catalog #27865, #27965)
• EasySep® hESC-derived CD34 Positive Selection Kit (Catalog #18167)
• mFreSR™ (Catalog #05854, #05855)
• CryoStor™CS10 (Catalog #07930)
|
|
Intended Use Statement:
|
For Research Use Only. Not for Therapeutic or Diagnostic Use.
|
|
Equipment Required:
|
The Jia publication uses the Amaxa nucleofector system (machine, program and reagents) for 1 of 3 transfections performed in the protocol. This may be useful to customers but may not be critical if they can achieve sufficient transfection efficiencies and survival with alternate reagents (will have to be determined and optimised by the end user).
Access to automated cell sorting may also be helpful to customers to sort for GFP positive cells after transfection so as to ultimately calculate the frequency of iPSC generation (iPSC clones/transfected cells).
|
|
Legal Statement:
|
*Patent Pending
*This product is for internal non-commercial research use only. No rights are conveyed to modify or clone the gene encoding fluorescent protein contained in this product. The right to use this fluorescent protein specifically excludes the right to validate or screen compounds. For information on commercial licensing, contact Evrogen Licensing Department, email: license@evrogen.com.
|
|
Advantages:
|
This is a nonviral, nonintegrating vector that can be either transfected or electroporated into cells to allow for expression of the reprogramming factors. The mini-circle plasmid remains episomal in the cell and is eventually lost from the dividing cells. This approach eliminates integration site expression variability and mutagenesis that is a drawback to viral approaches that have been used to date.
|